MOUNTAIN VIEW, Calif., March 21, 2012 /PRNewswire/ -- When deciding between the life sciences offerings of various market research organizations, the upcoming and existing research programs prove highly relevant. To meet this need, Frost & Sullivan introduces the Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012 compendium. This resource includes Frost & Sullivan's Life Sciences proposed key research for 2012, as well as the profiling of recent content over the last two years.
If you are interested in receiving the complimentary Frost & Sullivan Life Sciences Content: Pharmaceuticals, Biotechnology, In-Vitro Diagnostics and Life Sciences Research Tools, 2010 to 2012 compendium, please send an email to Britni Myers, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company Web site, city, state and country.
"The current trend in the pharmaceutical industry is to tackle incredibly complex disease areas with significant unmet needs," said Frost & Sullivan Life Sciences Global Program Manager Jennifer Brice. "Taking on these challenges requires developing novel drugs and biologics to treat the diseases. However, due to the increasing understanding of the role that heterogeneity of human and viral genomes plays in disease pathology and the likelihood of the success or failure of a drug, the 'one size fits all' model does not always work."
To address these highly varied obstacles, the compendium allows life science organizations to compare and distinguish products in the market most relevant to their needs and growth challenges. This may prove particularly handy when a company is attempting to understand potential expansion opportunities, seeking a merg
|SOURCE Frost & Sullivan|
Copyright©2010 PR Newswire.
All rights reserved